Fate Therapeutics, Inc. (NASDAQ:FATE) is among the best get rich quick stocks to buy now. Analysts at H.C. Wainwright have ...

Earlier use of combination therapies is purported to improve outcomes in many disease states, including lupus nephritis.

The study cohort comprised 41,095 patients with SLE, including 19,631 who received THA and 21,464 who received TKA. Overall, 30-day readmission rates were 6.1% for THA and 4.8% for TKA. Readmission ...

Business Wire Merck Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025 12 Jun 2025 DARMSTADT, Germany Not intended for UK-, US- or Canada ...

Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases. Promising results, but Phase ...

A study found that combining the active ingredient extracted from the traditional Chinese medicine Astragalus membranaceus with the widely used Western drug methotrexate can effectively reduce chronic ...

A research team, led by Professor Lin Xiang (first right) and Professor Shen Jiangang (second right), has discovered that combining the active ...

The Michael Jon Barlin Pediatric Lupus Research program provides funding for research projects that have the potential to significantly advance the field of or impact the lives of children living with ...

The U.S. Food & Drug Administration (FDA) has granted approval for a new subcutaneous autoinjector formulation of belimumab (Benlysta®) treatment for children ages five years and older with active ...

Belimumab is now the first and only subcutaneous biologic therapy approved for at-home administration in pediatric lupus nephritis.

With this approval, pediatric patients aged five years and older with active lupus nephritis will have a first-of-its-kind treatment option for at-home administration. Lupus nephritis is one of ...